Efficacy and Safety of Rimegepant 75 Mg Oral Tablet, a CGRP Receptor Antagonist, for the Acute Treatment of Migraine: A Randomized, Double-Blind, Placebo-Controlled Trial (vol 17, pg 2431, 2024)

被引：0
|
作者：
Lipton, R. b
Thiry, A.
Morris, B. a
Croop, R.
机构：
来源：
JOURNAL OF PAIN RESEARCH | 2024年 / 17卷
关键词：
D O I：
10.2147/JPR.S499096
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：4085 / 4086
页数：2
相关论文
共 50 条
  • [31] Onset of Migraine Preventive Effects With Rimegepant in a Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Trial
    Lipton, R. B.
    Kudrow, D.
    Smith, T.
    Croop, R.
    Jensen, C. M.
    Kamen, L.
    Thiry, A.
    Coric, V.
    Goadsby, P. J.
    JOURNAL OF HEADACHE AND PAIN, 2021, 22 (SUPPL 1): : 18 - 19
  • [32] Rizatriptan 5 mg for the acute treatment of migraine in adolescents: A randomized, double-blind, placebo-controlled study
    Winner, P
    Lewis, D
    Visser, WH
    Jiang, KH
    Ahrens, S
    Evans, JK
    HEADACHE, 2002, 42 (01): : 49 - 55
  • [33] Vaporized cannabis versus placebo for the acute treatment of migraine: a randomized, double-blind, placebo-controlled, crossover trial
    Schuster, Nathaniel
    Wallace, Mark
    Buse, Dawn
    Lee, Euyhyun
    Liu, Lin
    Marcotte, Thomas
    Sexton, Michelle
    CEPHALALGIA, 2023, 43 (1supp) : 23 - 24
  • [34] Safety and efficacy of rimegepant orally disintegrating tablet for the acute treatment of migraine in China and South Korea: a phase 3, double-blind, randomised, placebo- controlled trial (vol22, pg 476, 2023)
    Yu, S.
    Kim, B-K
    Guo, A.
    LANCET NEUROLOGY, 2023, 22 (10): : E11 - E11
  • [35] Safety and efficacy of anastrozole for the treatment of pubertal gynecomastia: A randomized, double-blind, placebo-controlled trial
    Plourde, PV
    Reiter, EO
    Jou, HC
    Desrochers, PE
    Rubin, SD
    Bercu, BB
    Diamond, FB
    Backeljauw, PF
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (09): : 4428 - 4433
  • [36] A randomized, double-blind, placebo-controlled study of oral almotriptan 6.25 mg, 12.5 mg, and 25 mg in the acute treatment of migraine in adolescents
    Linder, S. L.
    Mathew, N. T.
    Cady, R. K.
    Finlayson, G.
    Ishkanian, G.
    Lewis, D. W.
    Cabarrocas, X.
    ANNALS OF NEUROLOGY, 2006, 60 : S152 - S152
  • [37] The Efficacy and Safety of Milnacipran for Treatment of Fibromyalgiae. A Randomized, Double-blind, Placebo-controlled Trial
    Mease, Philip J.
    Clauw, Daniel J.
    Gendreau, R. Michael
    Rao, Srinivas G.
    Kranzler, Jay
    Chen, Wei
    Palmer, Robert H.
    JOURNAL OF RHEUMATOLOGY, 2009, 36 (02) : 398 - 409
  • [38] Efficacy and safety of corticosteroids in the treatment of CP/CPPS: A randomized, double-blind, placebo-controlled trial
    Dimitrakov, JD
    Tchitalov, J
    Dikov, D
    JOURNAL OF UROLOGY, 2004, 171 (04): : 61 - 62
  • [39] Onset of Migraine Preventive Effects With Rimegepant in a Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Trial
    Lipton, R. B.
    Kudrow, D.
    Smith, T.
    Croop, R.
    Jensen, C. M.
    Kamen, L.
    Thiry, A.
    Coric, V.
    Goadsby, P. J.
    CEPHALALGIA, 2021, 41 (1_SUPPL) : 27 - 28
  • [40] The efficacy and safety of milnacipran for treatment of fibromyalgia. A randomized, double-blind, placebo-controlled trial (vol 36, pg 398, 2009)
    Mease, P. J.
    Clauw, D. J.
    Gendreau, R. M.
    JOURNAL OF RHEUMATOLOGY, 2009, 36 (03) : 661 - 661
12345